PMID- 21769423
OWN - NLM
STAT- MEDLINE
DCOM- 20120113
LR  - 20141120
IS  - 1791-2423 (Electronic)
IS  - 1019-6439 (Linking)
VI  - 39
IP  - 4
DP  - 2011 Oct
TI  - Induction of specific human cytotoxic T cells using dendritic cells transduced 
      with an adenovector encoding rat epidermal growth factor receptor 2.
PG  - 907-13
LID - 10.3892/ijo.2011.1124 [doi]
AB  - This study demonstrates the ability to generate antigen-specific cytotoxic T 
      cells (CTLs) against HER2 using a xenoantigenic immune stimulation strategy. 
      Dendritic cells (DCs) were transduced with an adenovirus vector incorporating 
      full-length cDNA for rat (xenoantigen) epidermal growth factor receptor 2 
      (Adv-HER2). Stimulation of autologous T cells with Adv-HER2 infected DCs led to 
      enhanced HER2-specific reactivity as assessed by quantitative real-time 
      polymerase chain reaction (qRT-PCR) for T cell IFN-gamma mRNA. In ELISPOT and 
      intracellular cytokine staining (ICS) assays, CD8+ CTLs induced by Adv-HER2 
      transduced DCs released IFN-gamma following stimulation with irradiated autologous 
      DCs infected with Adv-HER2 or loaded with a human prostate cancer cell line 
      (LNCaP) lysate. DCs pulsed with HER2 peptides were less stimulatory than Adv-HER2 
      transduced DCs. HER2 DC induced CTL lysed HER2+ HLA-A2+ tumor cells (MCF-7); 
      significantly reduced lysis occurred in HER2+ HLA-A2- tumor cells (SKOV-3), and 
      the NK cell sensitive cell line K-562.
FAU - Suresh, Kalathil
AU  - Suresh K
AD  - Division of Urology, Sunnybrook Health Sciences Centre, University of Toronto, 
      Toronto, Canada.
FAU - Scheid, Elizabeth
AU  - Scheid E
FAU - Klotz, Laurence
AU  - Klotz L
FAU - Venkateswaran, Vasundara
AU  - Venkateswaran V
FAU - Gauldie, Jack
AU  - Gauldie J
FAU - Foley, Ronan
AU  - Foley R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20110714
PL  - Greece
TA  - Int J Oncol
JT  - International journal of oncology
JID - 9306042
RN  - 0 (Antibodies)
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (HLA-A2 Antigen)
RN  - 82115-62-6 (Interferon-gamma)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adenoviridae/genetics/metabolism
MH  - Animals
MH  - Antibodies/immunology
MH  - Antigens, Neoplasm/genetics/immunology/metabolism
MH  - Cancer Vaccines/genetics/immunology/metabolism
MH  - Cell Line, Tumor
MH  - Cytotoxicity, Immunologic/genetics/immunology
MH  - Dendritic Cells/immunology/*physiology
MH  - HLA-A2 Antigen/immunology
MH  - Humans
MH  - Interferon-gamma/antagonists & inhibitors/genetics/metabolism
MH  - K562 Cells
MH  - Killer Cells, Natural/immunology/metabolism
MH  - Lymphocyte Activation
MH  - Rats
MH  - Receptor, ErbB-2/biosynthesis/genetics/*immunology
MH  - T-Lymphocytes, Cytotoxic/*immunology
MH  - Transduction, Genetic/methods
EDAT- 2011/07/20 06:00
MHDA- 2012/01/14 06:00
CRDT- 2011/07/20 06:00
PHST- 2011/03/23 00:00 [received]
PHST- 2011/05/18 00:00 [accepted]
PHST- 2011/07/20 06:00 [entrez]
PHST- 2011/07/20 06:00 [pubmed]
PHST- 2012/01/14 06:00 [medline]
AID - 10.3892/ijo.2011.1124 [doi]
PST - ppublish
SO  - Int J Oncol. 2011 Oct;39(4):907-13. doi: 10.3892/ijo.2011.1124. Epub 2011 Jul 14.